Mark A. Hoffman
Experienced in Idiopathic Neutropenia

Dr. Mark A. Hoffman

Hematology | Oncology
2800 Marcus Avenue, 
New Hyde Park, NY 
On Staff At
Experienced in Idiopathic Neutropenia
2800 Marcus Avenue, 
New Hyde Park, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Hoffman is a Hematologist and an Oncologist in New Hyde Park, New York. Dr. Hoffman is rated as an Experienced provider by MediFind in the treatment of Idiopathic Neutropenia. His top areas of expertise are Breast Cancer, Endometrial Cancer, Adult Soft Tissue Sarcoma, and Inflammatory Breast Cancer.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
McGill University
Residency
Vancouver General Hospital
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NY
Fellowships
Montefiore Medical Center-Moses Division
Albert Einstein College of Medicine-Yeshiva University
Hospital Affiliations
Long Island Jewish Medical Center
North Shore University Hospital
Languages Spoken
English
French
Hebrew
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

2800 Marcus Avenue, New Hyde Park, NY 11042

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Pegylated Liposomal Doxorubicin
Study Phase: Phase 2
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Enrollment Status: Completed
Publish Date: March 08, 2022
Intervention Type: Drug
Study Drug: Bupropion Hydrochloride
Study Phase: Phase 2
View 2 Less Clinical Trials

4 Total Publications

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Journal: Gynecologic oncology
Published: June 10, 2020
Similar Doctors
Distinguished in Idiopathic Neutropenia
Dr. Mathew Lonberg
Hematology | Oncology
Distinguished in Idiopathic Neutropenia
Dr. Mathew Lonberg
Hematology | Oncology

White Plains Medical Diagnostic Services, PC

41 E Post Rd, 
White Plains, NY 
 (18.8 miles away)
914-681-1201
Languages Spoken:
English
See accepted insurances

Mathew Lonberg is a Hematologist and an Oncologist in White Plains, New York. Dr. Lonberg is rated as a Distinguished provider by MediFind in the treatment of Idiopathic Neutropenia. His top areas of expertise are Paget Disease of the Breast, Idiopathic Neutropenia, Chronic Lymphocytic Leukemia (CLL), and Schnitzler Syndrome.

Distinguished in Idiopathic Neutropenia
Dr. Kevin M. Troy
Hematology
Distinguished in Idiopathic Neutropenia
Dr. Kevin M. Troy
Hematology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Suite 6, 
New York, NY 
 (13.7 miles away)
212-241-4812
Languages Spoken:
English
See accepted insurances

Kevin Troy is a Hematologist in New York, New York. Dr. Troy is rated as a Distinguished provider by MediFind in the treatment of Idiopathic Neutropenia. His top areas of expertise are Factor 11 Deficiency, Thrombocytopenia, Idiopathic Neutropenia, Shwartzman Phenomenon, and Bone Marrow Aspiration.

Distinguished in Idiopathic Neutropenia
Dr. Lewis R. Silverman
Oncology | Hematology
Distinguished in Idiopathic Neutropenia
Dr. Lewis R. Silverman
Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Suite 6, 
New York, NY 
 (13.7 miles away)
212-241-4812
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lewis Silverman is an Oncologist and a Hematologist in New York, New York. Dr. Silverman is rated as a Distinguished provider by MediFind in the treatment of Idiopathic Neutropenia. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Idiopathic Neutropenia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoffman's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile